Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA).
Wang C, Zhou Y, Lin Y, Mao F, Guan J, Zhang X, Shen S, Wang X, Zhang Y, Pan B, Zhong Y, Peng L, Cao X, Yao R, Zhou X, Xu C, Xu Y, Sun Q.
Wang C, et al. Among authors: xu c, xu y.
BMC Cancer. 2022 Mar 14;22(1):269. doi: 10.1186/s12885-022-09346-1.
BMC Cancer. 2022.
PMID: 35287613
Free PMC article.